IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.577
AS - Asia 7.004
EU - Europa 5.037
SA - Sud America 932
Continente sconosciuto - Info sul continente non disponibili 650
AF - Africa 230
OC - Oceania 20
Totale 23.450
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.266
CN - Cina 2.888
SG - Singapore 1.651
IE - Irlanda 1.103
HK - Hong Kong 888
BR - Brasile 667
VN - Vietnam 657
IT - Italia 653
RU - Federazione Russa 595
DE - Germania 506
FI - Finlandia 494
FR - Francia 482
UA - Ucraina 426
GB - Regno Unito 263
SE - Svezia 225
IN - India 201
BD - Bangladesh 174
CA - Canada 145
ZA - Sudafrica 112
AR - Argentina 98
JP - Giappone 75
MX - Messico 73
IQ - Iraq 61
TR - Turchia 61
ID - Indonesia 54
PL - Polonia 48
NL - Olanda 47
CO - Colombia 39
PK - Pakistan 39
ES - Italia 33
BE - Belgio 32
EC - Ecuador 32
VE - Venezuela 28
MA - Marocco 27
SA - Arabia Saudita 27
PH - Filippine 23
MY - Malesia 22
AT - Austria 21
JM - Giamaica 20
JO - Giordania 20
AU - Australia 19
UZ - Uzbekistan 19
CL - Cile 17
LT - Lituania 17
EG - Egitto 16
PY - Paraguay 16
TN - Tunisia 16
IR - Iran 15
KE - Kenya 15
AE - Emirati Arabi Uniti 14
CZ - Repubblica Ceca 13
BO - Bolivia 12
KR - Corea 12
AZ - Azerbaigian 11
CR - Costa Rica 11
PE - Perù 10
IL - Israele 9
RO - Romania 9
DO - Repubblica Dominicana 8
EU - Europa 8
KZ - Kazakistan 8
MD - Moldavia 8
NP - Nepal 8
PA - Panama 8
UY - Uruguay 8
AL - Albania 7
DZ - Algeria 7
GR - Grecia 7
KG - Kirghizistan 7
LB - Libano 7
BA - Bosnia-Erzegovina 6
CH - Svizzera 6
DK - Danimarca 6
ET - Etiopia 6
NI - Nicaragua 6
OM - Oman 6
PS - Palestinian Territory 6
SN - Senegal 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
BH - Bahrain 5
CU - Cuba 5
CY - Cipro 5
HN - Honduras 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
CI - Costa d'Avorio 4
GY - Guiana 4
NG - Nigeria 4
QA - Qatar 4
AM - Armenia 3
BB - Barbados 3
BY - Bielorussia 3
GT - Guatemala 3
HU - Ungheria 3
KW - Kuwait 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
Totale 22.756
Salva come PNG Salva come JPEG
Città #
Dublin 1.100
San Jose 1.052
Chandler 1.019
Singapore 907
Hong Kong 871
Ashburn 869
Dallas 706
Jacksonville 577
Beijing 535
Nanjing 523
Council Bluffs 400
Boardman 364
Los Angeles 268
Lauterbourg 241
Princeton 220
New York 219
Ho Chi Minh City 215
Lawrence 202
Nanchang 201
Wilmington 184
Hebei 172
Hanoi 159
Helsinki 157
Changsha 144
Medford 143
Shenyang 140
Munich 132
Ann Arbor 130
Jiaxing 124
Santa Clara 124
Buffalo 113
Shanghai 110
Milan 107
Tianjin 106
Redondo Beach 103
Moscow 101
Johannesburg 90
Hangzhou 79
Pavia 76
Columbus 73
São Paulo 73
Tokyo 66
Orem 54
Seattle 53
Turku 52
The Dalles 46
Pune 45
Chennai 43
Falkenstein 42
Montreal 42
Frankfurt am Main 41
San Francisco 41
Toronto 37
Woodbridge 37
Stockholm 36
Warsaw 36
Chicago 35
Falls Church 35
Rome 35
Da Nang 33
Norwalk 33
Nuremberg 31
Brussels 30
Brooklyn 28
Guangzhou 28
Mexico City 28
Washington 27
Houston 25
Paris 25
Atlanta 24
Verona 24
Baghdad 23
London 23
Manchester 23
Ankara 22
Denver 22
Haiphong 21
Poplar 21
Belo Horizonte 20
Phoenix 20
Zhengzhou 20
Amsterdam 17
Dhaka 17
Fairfield 17
Amman 16
Tashkent 16
Des Moines 15
Boston 14
Brescia 13
Istanbul 13
Jakarta 13
Brasília 12
Hải Dương 12
Jinan 12
Kingston 12
Xi'an 12
Bến Tre 11
Curitiba 11
New Delhi 11
Quito 11
Totale 14.711
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 198
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 191
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 169
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 168
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 167
An insidious presentation of splenic marginal zone lymphoma 160
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 156
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 153
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 153
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 148
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 147
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 146
Blast phase of essential thrombocythemia: A single center study. 145
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 145
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 143
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 142
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 141
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 137
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 134
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 133
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders 132
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 131
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 129
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 128
Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer 128
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 127
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 126
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 126
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 125
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 125
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 121
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 121
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 121
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 121
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 120
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 119
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 119
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 118
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 118
A young woman with microcytic anemia and hypertransaminasemia 116
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice 115
Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas 115
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 113
Diagnosis and management of prefibrotic myelofibrosis. 113
Everolimus in diffuse large B-cell lymphomas 112
Case Report: A rare case of small bowel obstruction secondary to plasma cell myeloma 110
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 110
Antiviral therapies for managing viral hepatitis in lymphoma patients 110
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network 110
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 109
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 108
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 108
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. 108
ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center 108
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 107
Retrospective Investigation of Human Papillomavirus Cervical Infection and Lymphoma Incidence: A Clinical and Pathological Evaluation 107
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 107
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 107
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. 106
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network 106
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 105
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 105
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 105
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 104
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 104
A paraumbilical lymphomatous mass 103
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 103
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 102
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 102
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 101
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 101
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 100
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 99
Role of the molecular staging and response in the management of follicular lymphoma patients 99
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 98
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 98
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 98
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 98
Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy 98
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders 98
Transient response of myeloma clone to pamidronate therapy 97
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 97
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 96
Double expressor and double/triple hit status among primary cutaneous diffuse large B cell lymphoma: A comparison between leg type and NOS Subtypes 96
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2) 95
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 95
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 95
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 95
Genetic characterization and clinical features of helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma 94
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease 94
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. 93
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 93
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins 93
Mantle cell lymphoma of mucosa-associated lymphoid tissue: A european mantle cell lymphoma network study 93
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial 93
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 92
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 92
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 92
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. 90
Totale 11.721
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.642
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.642
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022949 0 5 19 15 38 55 19 56 53 40 141 508
2022/20232.990 277 196 21 239 279 318 27 177 1.257 28 111 60
2023/20241.404 147 234 60 97 107 395 34 84 12 53 74 107
2024/20253.794 116 269 74 88 78 233 349 242 846 136 466 897
2025/20269.022 637 663 1.000 1.009 956 351 1.818 325 798 700 479 286
2026/2027903 352 551 0 0 0 0 0 0 0 0 0 0
Totale 23.450